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Theaimofthepresentstudywastomakeuseoftheartiﬁciallyinducedagingmodelcardiomyocytestofurtherinvestigatepotential
anti-aging-associated cellular diastolic dysfunction eﬀects of EGB761 and explore underlying molecular mechanisms. Cultured rat
primary cardiomyocytes were treated with either D-galactose or D-galactose combined with EGB761 for 48h. After treatment,
the percentage of cells positive for SA-β-gal, AGEs production, cardiac sarcoplasmic reticulum calcium pump (SERCA) activity,
the myocardial sarcoplasmic reticulum calcium uptake, and relative protein levels were measured. Our results demonstrated that
in vitro stimulation with D-galactose induced AGEs production. The addition of EGB761 signiﬁcantly decreased the number of
cells positive for SA-β-gal. Furthermore, decreased diastolic [Ca2+]i, curtailment of the time from the maximum concentration
of Ca2+ to the baseline level and increased reuptake of Ca2+ stores in the SR were also observed. In addition, the level of p-
Ser16-PLN protein as well as SERCA was markedly increased. The study indicated that EGb761 alleviates formation of AGEs
products on SERCA2a in order to mitigate myocardial stiﬀness on one hand; on other hand, improve SERCA2a function through
increase the amount of Ser16 sites PLN phosphorylation, which two hands ﬁnally led to ameliorate diastolic dysfunction of aging
cardiomyocytes.
1.Introduction
Diastolic heart failure (DHF) is most commonly seen in
elderly patients and women with a history of diabetes,
hypertension, obesity, cardiac ischemia, and so on. Existing
research revealed that elevated oxidative stress, NAD(P)H
oxidase expression, protein carbonyl formation, protein
oxidation,andproteinmodiﬁcationaswellasenhancedAGE
level have been found in aged cardiac myocytes [1]. The
major cause for DHF is cardiac aging, which is referred
to as a dramatic decline in cardiac pump function with
advanced age and resulted in diastolic dysfunction [2, 3].
Due to lack of understanding the mechanism of cardiac
diastolic dysfunction, current clinical treatment for patients
with DHF is disappointing [4–6]. Therefore, understanding
mechanism of aging myocardial diastolic dysfunction in
molecular level is especially important for the speciﬁc
therapeutic targets of DHF association with aging.
D-galactose is a reducing sugar that reacts readily with
the free amines of amino acids in proteins and peptides
both in vitro and in vivo to form advanced glycation
endproducts (AGEs) [4]. AGE is increased during aging
and has been linked to the pathogenesis of many age-
associated pathologies such as diabetes, arteriosclerosis,
nephropathy, infection, and Alzheimer’s disease [5]. Our
previous study demonstrated that D-galactose injection led
to accelerated aging phenotypes manifested by an increased
AGEs level, and aging rats fed with D-galactose present2 Oxidative Medicine and Cellular Longevity
signiﬁcant cardiac remodeling compared with adult rats,
which was manifested by increased left ventricular posterior
wall and interventricular septal thickness and by increased
left ventricular weight and impaired diastolic function. The
contents of MDA, mtDNA, and AGEs were signiﬁcantly
increased; however, the contents of SOD and GSH-PX were
decreased.Therefore,wehavesimulatedagingprocessinvivo
by D-galactose intervention in order to study aging-related
cardiac diastolic dysfunction.
The incidence of cardiac diastolic dysfunction is related
to an elevated myocardial stiﬀness and the resting tension
(Fpassive) which led to diastolic capacity decline. The increase
in myocardial stiﬀness is mainly related to AGEs cross-
linking with collagen deposition on myocardial interstitium,
whereas the latter is mainly related to abnormal myocar-
dial sarcoplasmic reticulum calcium transport regulatory
proteins which led the intracellular calcium overload in
diastolic phase [6]. Dysregulation of intracellular calcium
homeostasis plays a signiﬁcant role in the aged myocardial
cell, which leads to diastolic heart failure. An excessive
increase in the intracellular concentration of Ca2+ and
impaired translocating calcium ions from the cytosol to the
lumen of the sarcoplasmic reticulum would result in Ca2+
overload and thus produce myocardial diastolic dysfunction
[2].
As intracellular calcium is mainly regulated by the activ-
ity of myocardial sarcoplasmic reticulum calcium transport
regulatoryproteins,removalofcalciumfromthecytosolmay
be delayed by a decrease in the activity of sarco/endoplasmic
reticulum calcium adenosine triphosphate (SERCA) or an
increase in the level of activity of phospholamban (PLN),
which is a SERCA-inhibitory protein [7]. SERCA and PLN
dysfunction may lead to intracellular calcium overload,
which further arouse diastolic dysfunction [8].
EGb761 is a standard extract from the leaves of Ginkgo
biloba (Yinxing) containing 24% ginkgo-ﬂavone glycosides
(e.g., kaempferol, quercetin, and isorhamnetin derivatives)
and 6% terpenoid (e.g., ginkgolides A, B, C, J and bilobalide)
[9]. Numerous studies have shown that the ﬂavonoid
components scavenge superoxide, hydroxyl radicals, and
nitric oxide (NO) and protect myocardia from ischemia-
reperfusion injury [10–13], and the terpenoid constituents
also showed their cardioprotective eﬀects independent from
the free radical-scavenging properties [14].
The cardioprotective eﬀects of EGb761 have been
demonstrated in various in vivo and in vitro animal models
and humans. The existing literature [12, 15], including
our prophase research, has highlighted that EGb761 has
particular antiaging eﬀects on cardiomyocytes by inhibiting
nonenzymatic glycation and reducing the deposition of
AGEs in myocardium tissues [12, 16]. However, due to
cardiac aging which is referred to diastolic dysfunction, it
is unclear yet whether EGb761 can regulate myocardial sar-
coplasmicreticulumcalciumtransportregulatoryproteinsto
improve the diastolic function of aging cardiomyocytes. In
this study, we then aimed to investigate the possible action
and its molecular mechanisms in cultured D-galactose-
induced aging rat cardiomyocytes of treatment EGB761.
2.MaterialsandMethods
2.1. Drugs and Reagents. Standard EGb761 preparation
that we used mainly contains 4.2mg ﬂavonoid from Dr.
Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany);
D-galactoseandcaﬀeine were purchased fromSigma Aldrich
Inc (G5388; C1778); Dulbecco’s modiﬁed Eagle’s medium
(DMEM) and fetal calf serum (FCS) were purchased from
Gibco Invitrogen (31600-034; 16000044); senescence β-
galactosidase (β-gal) staining kit was purchase from Cell
Signaling(no.9860);ratAGEsELISAkitwaspurchasedfrom
ADLTechnologyInc(E0263r).Theenhancedchemilumines-
cence (ECL) Western blotting detection kit was purchased
from Pierce Rockford, IL, USA. Other materials used are
speciﬁed in detail in the following sections.
2.2. Primary Culture of Cardiomyocytes. Neonatal cardiomy-
ocytes were obtained from 20 Sprague-Dawley rats aged 1-2
days.Cardiactissuewasharvestedusingpreviouslydescribed
protocolswithminormodiﬁcations[17].Theventriclesfrom
the rats were minced and dissociated in 0.06% trypsin at
37◦C. The dissociated myocytes were placed into DMEM
supplemented with 20% fetal calf serum and 100U/mL
penicillin and streptomycin in a 50mL Corning cell culture
ﬂask for 1.5h at 37◦Cw i t h5 %C O 2, which minimized
nonmyocyte cells by adhesion to the bottom of the ﬂask.
The nonattached myocytes were then removed and plated
(5–6 × 105/mL) into a six-well culture cluster at 37◦Ci n
room air with 5% CO2. After incubation for 48h, 80%
of the attached myocytes were beating spontaneously and
were used for further experiments. All procedures were
performed in accordance with the Guide for the Care and
Use of Laboratory Animals (National Institutes of Health
Publication no. 85-23, revised 1996).
2.3. D-Galactose Treatment Protocol. The treatment protocol
for D-galactose induction was as previously described [18].
Once the attached myocytes were beating spontaneously,
the DMEM supplemented with 20% fetal calf serum was
removed, and DMEM supplemented with 5g/L D-galactose
was added to the cardiomyocytes in the culture cluster
for a further 48h incubation period. In addition, for the
cardioprotection study, EGB761 plus D-galactose was added
into the culture media at concentrations of 5, 10, and
20μg·mL−1 throughout the treatment.
2.4. SA β-Gal Staining. Senescence-associated β-gal (SA-β-
gal) activity was measured with the β-gal staining kit at pH
6.0 according to the instructions from the manufacturer.
Brieﬂy, cells were washed in phosphate buﬀered saline (PBS),
ﬁxed for 10–15min at room temperature with 1mL of
ﬁxative solution and incubated overnight at 37◦C with the
staining solution mix. Cells were observed for development
of the blue coloration with a microscope at a magniﬁcation
of ×400.
2.5. AGEs ELISA Assay. T h eA G E sa s s a yw a sp e r f o r m e d
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manufacturer. The reagents of the test kit were placed at
room temperature for 30min and diluted 1:20 with distilled
water. Aliquots of 100μL of the standards and samples
were added to blank micropores and 50μLe n z y m em a r k e r
solution was added. Microtiter plates were incubated at 37◦C
for 60min and then washed ﬁve times and put aside for 10–
20s each time. The A and B substrate solutions (50μL) were
added into the microtiter plates for 15min dark reactions
at 37◦C. The reaction was terminated by the addition of
50μL stop solution, and the optical density (OD) at 450nm
was determined by an ultra microplate reader (ELX 808IU,
Bio-Tek Instruments Inc.). An AGEs standard curve was
generatedandtheAGEsvaluesofthesampleswerecalculated
from the standard curve.
2.6.MeasurementofCardiacSERCAActivity. SERCAactivity
was determined by a modiﬁed p-nitrophenyl phosphate
(p-NPP) method routinely used in our laboratory [19].
Brieﬂy, cardiomyocytes were homogenized and centrifuged
at 4◦C for 15min. A 10μL aliquot of supernatant was
preincubated for 10min at 37◦Cw i t h8 0μLb u ﬀer solution
containing: 10μLM g C l 2,1 0 μLE G T A ,1 0 μLK C l ,3 0o r
40μL HEPES (pH 7.4), and 10μL 0.01% TritonX-100, either
with or without 10μLC a C l 2. The phosphatase reaction was
started by the addition of 10μL 10mM p-NPP disodium
salt hexahydrate and stopped after 30min by the addition
of 100μL 500mM Tris (pH 8.7) and 55mM EDTA. The
liberated p-nitrophenol was measured by an ultra microplate
reader (ELX 808IU) at a wavelength of 405nm and a
standard curve was generated. The SERCA activity was
expressed as the amount of p-nitrophenol produced per
gram of protein in a minute (μmol/g/min).
2.7. Measurement of [Ca2+]i and SR Ca2+ Load. Field
myocyte on the cell culture dishes (Corning Inc) and [Ca2+]i
were measured as previously described [19], using Fura-
2/AM (2.0μM, Invitrogen) for 30min at 37◦C. SR Ca2+
load was measured as the Δ[Ca2+]i amplitude upon rapid
exposure to 10mM caﬀeine. The ratio of background-
corrected ﬂuorescence at 340nm excitation to 380nm exci-
tation (F340/F380 ratio) was regarded as [Ca2+]i.T h et i m e
from the maximum concentration of Ca2+ to the baseline
level was regarded as the time of SR Ca2+ uptake.
2.8. Western Blot. Cells were lysed with ice-cold Cell Lysis
Reagent containing protease and phosphatase inhibitors (Bi
Yun Tian, China, P0013) to extract cytoplasm proteins. The
protein concentrations of the cytoplasm were determined
by bicinchoninic acid (BCA) protein concentration deter-
mination. Equal amounts of protein extracts were separated
to 16% SDS/PAGE and blotted onto a polyvinylidene
diﬂuoride (PVDF) membranes (Millipore, Technology Inc).
The membrane was blocked and probed overnight at 4◦C
with primary antibodies against SERCA2a (1:1000, ARB
Inc.) and Ser16/Thr17-phosphorylated phospholamban (p-
PLN) (1:1000, Abcam Inc/1:100, Santa Cruz Inc) and
GAPDH (1:3000, Sigma), followed by incubation with
horseradish-peroxidase-conjugated secondary antibody for
1h at room temperature. Blots were developed using an
ECLdetectionsystemandexposedtoX-rayﬁlm.Normalized
bands densities were analyzed by Gel-pro analyzer software
and expressed as ratios to GAPDH.
2.9. Statistical Analysis. A l ld a t aa r ep r e s e n t e da sm e a n±
standard deviation (SD). Statistical analysis was performed
byANOVAformultiplecomparisons.Origin7.0(OriginLab,
USA)wasusedtoperformallstatisticalanalysis.Ineachcase,
P<0.05 was considered statistically signiﬁcant.
3. Results
3.1. EGB761 Prevented against Increased Numbers of SA
β-Gal-Positive Cells and Formation of AGEs. To investi-
gate whether cardiomyocytes-treated D-galactose showed a
senescent phenotype, we examined the numbers of SA β-
gal-positive cells in all groups of cardiomyocytes. In D-
galactose-induced cardiomyocytes, the ratio of SA β-gal-
positive cardiomyocytes was signiﬁcantly increased than that
of control cardiomyocytes. The addition of EGB761 signiﬁ-
cantly decreased the number of cells positive for SA-β-gal in
a dose-dependent manner, with an optimal concentration of
20μg·mL−1 (n = 20 number of rats each group and n = 6
experimental replicates; P<0.05 versus D-galactose).
Meanwhile, AGEs are considered as one of the important
markers in cardiac aging. In the present study, AGEs content
was signiﬁcantly increased in the D-galactose-treated group.
Signiﬁcantly decreased AGEs level was observed in diﬀerent
concentrationsofEGB761treatmentgroups(n = 20number
of rats each group and n = 6 experimental replicates; P<
0.05 versus D-galactose) (Table 1 and Figure 1).
3.2. The Eﬀect of EGB761 on the Intracellular [Ca2+]i and
SR Ca2+ Load. Intracellular Ca2+ overload is suggested to
be one of the main factors involved in DHF. We then
used the Ca2+ indicator Fluo2/AM to determine the eﬀect
of AGEs on the intracellular [Ca2+]i, the time that Ca2+
uptake into sarcoplasmic reticulum and SR Ca2+ load. In
the D-galactose group, an increased diastolic [Ca2+]i was
observed, and the time from the maximum concentration
of Ca2+ to the baseline level was prolonged compared with
the controls (P<0.05). After perfusion with 10mM
caﬀeine, the amplitude of the caﬀeine-induced calcium
transient (Δ[Ca2+]i) also declined in D-galactose-treated
group. However, above-mentioned eﬀects were reversed by
20μg·mL−1 EGB761 (n = 20 number of rats each group and
n = 6 experimental replicates; P<0.05 versus D-galactose).
Representative changes in the ratio are shown in Table 2.
3.3. The Eﬀect of EGB761 on SERCA Activity in Car-
diomyocytes. To investigate the mechanism of EGB761 on
intracellular [Ca2+]i and SR Ca2+ load., the SR Ca2+-ATPase
(SERCA) activity in the cardiomyocytes was measured
(Table 3). An obvious suppression of SERCA activity was
observed in the D-galactose group, and this inhibition eﬀect
was attenuated by 20μg·mL−1 EGB761 treatment (n = 204 Oxidative Medicine and Cellular Longevity
Table 1: Eﬀects of EGB761 on the numbers of SA β-gal-positive cell and formation of AGEs.
Group Control
(N = 20)
5g·L−1
D-galactose
(N = 20)
5g·L−1 D-galactose +
5μg·mL−1 EGB761
(N = 20)
5g·L−1 D-galactose +
10μg·mL−1 EGB761
(N = 20)
5g·L−1 D-galactose +
20μg·mL−1 EGB761
(N = 20)
The percentage of SA
β-gal-positive cell (%) 17.15 ±2.97 5 .6 ±4.9a 57.7 ±7.9b 49.7 ±9.2c 34.0 ±6.6d
AGEs content (pg/mL) 93.22 ±26.14 702.58 ±32.16a 404.36 ±32.94b 356.77 ±25.32c 248.72 ±77.26d
(Data are means ± SD, n = 6 experimental replicates, aP<0.05 Versus control group; bP<0.05, cP, dP<0.05 Versus D-galactose group).
Table 2: Eﬀects of EGB761 on intracellular diastolic [Ca2+]i, the time from the maximum concentration of Ca2+ to the baseline level and SR
Ca2+ load (Δ[Ca2+]i (%)).
Group Control
(N = 20)
5g·L−1 D-galactose
(N = 20)
5g·L−1 D-galactose + 20μg·mL−1 EGB761
(N = 20)
([Ca2+]i)D 0.59 ±0.06 0.71 ±0.08a 0.61 ±0.07b
tβ(ms) 775.15 ±121.68 1000.95 ±129.34a 834.36 ±301.85d
Δ[Ca2+]i (%) 0.53 ±0.19 0.11 ±0.02a 0.47 ±0.16b
(Data are means ± SD, n = 6 experimental replicates, aP<0.05 versus control group; bP<0.05 versus D-galactose group).
Table 3: Eﬀects of EGB761 on sarcoplasmic reticulum calcium
pump (SERCA2a) activity.
Group SERCA2a activity
(μmol/g/min)
Control 2.68 ±0.35
5g·L−1 D-galactose 1.60 ±0.28a
5g·L−1 D-galactose + 20μg·mL−1 EGB761 2.43 ±0.44b
(Data are means ± SD, n = 6 experimental replicates, aP<0.05 versus
control group; bP<0.05 versus D-galactose group).
numberofratseachgroupandn = 6experimentalreplicates;
P<0.05 versus D-galactose).
3.4. The Eﬀect of EGB761 on Sarcoplasmic Reticulum Calcium
Transport Regulatory Proteins Expression in Cardiomyocytes.
In order to investigate the underlying mechanisms of
EGB761 protecting against aging-associated diastolic dys-
function in cardiomyocytes, protein levels of calcium trans-
port regulatory proteins were measured by Western blot. As
shown in Figure 2, an approximately 60% downregulation of
SERCA2a protein expression was observed in D-galactose-
treated cardiomyocytes, while it was increased in addition
of EGB761 compared with the D-galactose group (P<
0.05). Since the inhibitory eﬀect of PLN on SERCA2a
was dependent on the phosphorylation level of PLN, p-
Ser16-PLN and p-Thr17-PLN protein expressions were then
measured. As shown in Figure 2, the level of p-Ser16-PLN
protein expression was markedly decreased by 54% in the D-
galactose-treated cardiomyocytes compared with the control
group, while it was increased in the EGB761 group (P<
0.05 versus D-galactose). However, the level of p-Thr17-PLN
protein expression showed no signiﬁcant changes in any
groups (n = 20 number of rats and n = 6 experimental
replicates; P<0.05 versus D-galactose).
4. Discussion
With the discovery of in vivo derived AGEs and then
severalcell-surfaceAGE-bindingproteins,muchresearchhas
been devoted to studying AGE formation and the potential
biologicaleﬀectsofAGEs[20].Severalearlierreportsshowed
that free radicals were increased in D-galactose-treated
animals and suggested that the increased free radicals may
account for the underlining mechanism responsible for the
acceleration of aging [21, 22]. However, data in earlier
study from Song et al. has shown that the aging change
is not D-galactose speciﬁc and aminoguanidine as an AGE
inhibitor preventing sugar-induced aging changes suggests
that glycation, rather than free radicals, is the major cause
of aging in this model [4]. In our current study, myocardial
cells chronical incubation with D-galactose has been used
as an artiﬁcially induced cardiomyocytes aging model for
AGEs formation and to further investigate potential anti-
aging-associated diastolic dysfunction eﬀects of EGB761 and
underlying molecular mechanisms.
The senescent phenotypes are associated with a typi-
cal gene expression proﬁle [23]; a senescent morphology
increases in senescence-associated β-galactosidase (SA β-
gal) activity [24]. Our data showed that the numbers of
SA β-gal-positive cells were signiﬁcantly increased in all
of cardiomyocytes after D-galactose treatment for 48h.
Meanwhile, intracellular AGEs content was signiﬁcantly
elevated compared with control group. It is conﬁrmed
that D-galactose-induced cardiomyocytes aging model was
successfully established in vitro. It is in agreement with those
ideas in the previous literature that is accumulation of AGEs
may associate with aging [1]. When EGB761 was included,
however, the numbers of SA β-gal-positive cells and intra-
cellular AGEs content were signiﬁcantly decreased, which
may indicate that EGB761 can attenuate the intracellular
formation of AGEs and delay the cellular senescence.
Relaxation dysfunction has been indicated in the aging
myocardium [25]. At the cellular level, depressed relaxationOxidative Medicine and Cellular Longevity 5
Control D-galactose D-galactose + EGB761
(×400)
Figure 1: Response of neonatal rat cardiomyocytes to 5g·L−1 D-galactose and 5g·L−1 D-galactose combined with 20μg·mL−1 EGB761 for
48h. Phase-contrast images showing morphologic changes and stained cells. (SA-β-gal positive cells; Blue, magniﬁcation ×400).
reﬂects impaired removal of cytosolic Ca2+ and reduced
cardiac SR Ca2+ loading. Data from our present study
depicted that AGEs accumulated on cardiomyocytes lead
to impaired intracellular Ca2+ handling, which is the main
cause of increased diastolic [Ca2+]i and a prolonged relax-
ation duration in aged cardiomyocytes. Meanwhile, similar
with the results previous reported by Petrova et al. [26].
As early as 1996, it was reported that all of these Ca2+
removal systems are functionally inhibited in diabetes [27].
Our results also demonstrated that caﬀeine-induced Ca2+
transients,anindicationofthereserveofCa2+ intheSR,were
signiﬁcantly reduced. However, given EGB761 couldincrease
reuptake of Ca2+ stores in the SR, curtailment of the time
of SR Ca2+ uptake and a decrease in the diastolic [Ca2+]i in
cardiomyocytes. These ﬁndings have suggested that EGB761
may protect against aging-associated diastolic dysfunction in
cardiomyocytes.
Simultaneously Ca2+ cycling is a critical determinant
of cardiomyocyte contractility and dilation. In mammalian,
duringrelaxation,about70%ofcytosolicCa2+ ispartlytaken
back into the sarcoplasmic reticulum by SERCA2a under
the regulation of PLN and partly extruded to the external
medium through the action of plasma membrane Ca2+
ATPase (PMCA,2%) and the Na+/Ca2+ exchanger (NCX,
28%) [28]. Thus, changed level and/or activity of SERCA2a
protein and/or its regulatory protein PLN may inﬂuence
the homeostasis of cardiac intracellular Ca2+ [29]. As the
PLN phosphorylation status is the key factor regulating the
function of SERCA, the main phosphorylation status of
Ser16 and Thr17 sites of PLN was investigated in our study
[30].OurdatarevealedasigniﬁcantsuppressionofSERCA2a
function including the activity and protein level due to AGEs
accumulation. It is consistent with the results of Bidasee et
al. They have shown for the ﬁrst time that prolongation
of cardiac relaxation rate may be attributed to diabetes-
induced increase in formation of AGEs (crosslinking as well
asnoncrosslinking)onSERCA2aindiabeticcardiomyopathy
rat. In addition, they also have found that the formation of
AGEs may decrease the amount of serine-16 and threonine-
17 phosphorylation of PLN [31].
However, in case of EGB761 additive, the eﬀect of
suppression was relieved. Followed by the next experiment,
in ordertodetermine whichphosphorylation residueof PLN
was involved in EGB761 protecting against aging-associated
diastolic dysfunction in cardiomyocytes, we determined the
amount of p-Ser16-PLN and p-Thr17-PLN protein. Our
data showed that decreased p-Ser16-PLN protein level was
observed in D-galactose-treated cardiomyocytes; while it
was increased in the EGB761 group compared with the D-
galactose group (P<0.05). However, the protein level of
p-Thr17-PLN showed no signiﬁcant changes in any of the
groups compared with the control cells (P>0.05). Thus,
theseresultsmayimplythattheactivityandphosphorylation
status of SERCA and PLN are involved in the pathogenesis
of cardiac diastolic dysfunction. It was possible that EGB761
could upregulate SERCA2a function through improvement
of the amount of Ser16 sites PLN phosphorylation, further
improvingthehomeostasisimpairmentofintracellularCa2+.
Since standard EGb761 preparation that we used mainly
contains 4.2mg ﬂavonoid and other unknown complex
composition, our results are consistent with the reports
demonstrating that ﬂavonoid components exhibit better
eﬀects than ginkgolides and bilobalides on protection of
SERCA2a function through increasing the amount of Ser16
sites PLN phosphorylation, which decline the intracellular
calcium overload [32]. Abdel-Kader et al. also have con-
ﬁrmed that quercetin showed a similar antioxidant eﬀect as
EGb761, suggesting that ginkgo-ﬂavone glycosides may be
the major components of EGb761 and other unknown com-
plex compositions eﬀect on the endoplasmic reticulum, and
other phenotypes tested in our paper may be multifactorial,
including its antioxidant, antiglycemic and other properties
[32, 33]. In our present study, we treat EGb761 plus D-
galactose incubation cardiomyocytes that can eﬀectively
and extensively counteract this action of aging-associated
diastolic dysfunction. It may be indicated that EGB7616 Oxidative Medicine and Cellular Longevity
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Figure 2: Eﬀect of EGB761 on SERCA2a, Ser16-phosphorylated
PLN (p-Ser16 PLN), Thr17-phosphorylated PLN (p-Thr17 PLN)
protein levels. Representative immunoblots for SERCA2a: p-Ser16
PLN, p-Thr17 PLN, and GAPDH in samples obtained from the
control (lane 1), D-galactose (lane2), D-galactose + EGB761 (lane
3).SummarizeddatashowingSERCA2a,p-Ser16PLN,andp-Thr17
PLN protein expression normalized. Values are expressed as mean
± SD (n = 4, aP<0.05 versus control group; bP<0.05 versus D-
galactose group).
extract may be a hypothetical preventive therapy in ageing
and AGE- related disease and may potentially protect the
heart from AGEs formation [11].
Taken together, due to cardiac diastolic dysfunction
which is related to an elevated myocardial stiﬀness and
the resting tension (Fpassive), it is possible that EGB761
at least partially attenuates the nonenzymatic glycation
formation AGEs (crosslinking as well as noncrosslinking)
on SERCA2a in cardiomyocytes on one hand, so that it
m i t i g a t e sm y o c a r d i a ls t i ﬀness. On other hand, it improves
SERCA2a function through increasing the amount of Ser16
sites PLN phosphorylation, which declines the intracellular
calcium overload in diastolic phase. The two hands eﬀects
of EGB761 may possibly protect against aging-associated
diastolic dysfunction in cardiomyocytes. In this case, the
EGB761 extract or some of its compounds may be a
novel therapeutic strategy in the prevention of the cardiac
alterations in diastolic dysfunction for the patients in clinical
practice.
5. Conclusions
In summary, EGb761, as an “antiaging” herb, has been used
in China for thousands of years which can treat aging-
associated diseases. Our work is the ﬁrst one to directly
prove the anti-aging-associated diastolic dysfunction eﬃcacy
of EGB761 in cardiomyocytes in vitro. EGb761 may alleviate
myocardial stiﬀness and the resting tension (Fpassive), thus,
protecting against aging-associated diastolic dysfunction in
cardiomyocytes.
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